Business
Novo to buy mid-stage heart failure biotech Cardior for up to $1.1B - Endpoints News
Novo Nordisk plans to acquire German biotech Cardior Pharmaceuticals, a Phase 2 RNA startup, for up to $1.1 billion to boost its presence in cardiovascular disease, the Danish drug giant said Monday morning. The move comes three weeks after Novo's ob
By: Endpoints News
- Mar 26 2024
- 0
- 0 Views
Novo Nordisk plans to acquire German biotech Cardior Pharmaceuticals, a Phase 2 RNA startup, for up to $1.1 billion to boost its presence in cardiovascular disease, the Danish drug g… [+614 chars]
Related
Share this page
Guest Posts by Easy Branches
